HIGHLIGHTS
- who: N.J. Lipton ba and collaborators from the (UNIVERSITY) have published the research: Willingness of women with early estrogen receptor-positive breast cancer to take adjuvant CDK4/6 inhibitors, in the Journal: (JOURNAL)
- what: The authors aimed to estimate the percentage of postmenopausal women with er+, her 2- breast cancer who would be willing to take a cdk4/6 inhibitor in addition to standard adjuvant et. The findings in this study support the importance of physicians recognizing the emotional factors that influence patient decision-making and ensuring that patients truly understand the objective benefits . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.